Orlistat is used to treat obesity (Weight loss) along with a reduced calorie and lower-fat diet in adults (18 years and above).
Orlistat: Anti-obesity drugs
Orlistat works by attaching to the enzymes in your digestive system (lipases) and preventing them from breaking down some of the fat that you’ve consumed during your meal. The fat that is not digested cannot be absorbed and it is removed by your body.
Consult your doctor if you experience:
Healthy weight loss
Top tips for healthy weight loss:
To help you find out if you have a healthy body weight, measure your and waist circumference To lose weight, the energy you take in from food must be less than the energy you use – eat less, move more!
Set yourself realistic goals to achieve a healthy weight. Even small amounts of weight loss can have significant health benefits and can help to set you on a path to a healthier future. Guidelines recommend that you should try to lose weight gradually, about 1-2 lbs (approximately 0.5-1.0 kg) a week
Weight loss can reduce your risk of: heart disease, stroke, type 2 diabetes and some cancers.
It can also reduce the risk of:
High blood pressure Angina (heart condition causing chest pain) High blood cholesterol levels Lower back and joint pain Fertility problems BMI and waist circumference
For most adults:
A BMI between 18.5 and 25 is defined as healthy. A BMI of over 25 is defined as overweight. A BMI of over 30 is defined as obese.
Waist-circumferences for which there is an increased risk and high risk of obesity-related health problems:
Increased risk High risk Men ≥94 cm (37 in) ≥102 cm (40 in) Women ≥80 cm (31.5 in) ≥88 cm (34.5 in)
Sensible weight loss should be seen as an overall lifestyle change which involves eating a healthy balanced diet and doing plenty of physical activity.
Guidelines recommend that you should try to lose weight gradually, about 1-2 lbs (approximately 0.5-1.0 kg) a week. This way, the weight is more likely to stay off. This rate of weight loss is based on using up 600 kcal per day more than you take in. On average, this means consuming no more than 1,400 kcal a day if you are a women, and no more than 1,900 kcal a day if you are a man. The amount of weight you lose will depend on how much weight you need to lose and how active you are.
Further information can be found on the manufacturers
Side Effects
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Tell your doctor or pharmacist as soon as possible if you do not feel well while you are taking Orlistat.
The majority of unwanted effects related to the use of Orlistat result from its local action in your digestive system. These symptoms are generally mild, occur at the beginning of treatment and are particularly experienced after meals containing high levels of fat. Normally, these symptoms disappear if you continue treatment and keep to your recommended diet.
Very common (may affect more than 1 in 10 people):
headache abdominal pain/discomfort urgent or increased need to open the bowels flatulence (wind) with or without discharge oily discharge, oily or fatty stools liquid stools low blood sugar levels (experienced by some people with type 2 diabetes) upper respiratory infections flu (influenza)
If you are using Orlistat alongside other medicines you may not be affected by other medicines. You can tell your doctor about all medications you are taking, including over-the-counter drugs,abolic products,non-hormonal medicines and dietary products. Orlistat is an oral medicine which contains the active ingredient sorbitol. This helps to decrease the absorption of fat from the body, it does not affect the absorption of sodium and alcohol in the body. Orlistat does not affect the absorption of potassium.
You are advised to take Orlistat for at least 7 days before engaging in activity to prevent any side effects you may develop. Orlistat does not affect the amount of potassium you are able to take. To find out if you are low level, avoid excessive drinking of alcohol, excessive sunlight deals Orlistat can interfere with the function of the kidney tubules that are normally involved in the absorption of potassium. You should also avoid the activity of another drug in the same course, other medicines may affect the action of Orlistat. If you have had any reactions while taking Orlistat, you should tell your doctor immediately. You should also avoid the activity of any other drug in the same course, other products may affect the action of Orlistat.
The UK's Food Standards agency is considering taking action to ban the import of prescription drugs containing orlistat. The decision follows a recent decision by the Department of Health and Social Care (DHSC) to remove the drug from the market.
The Medicines and Healthcare products Regulatory Agency (MHRA) said the decision by the DHSC was "not a good move". The decision was based on a review of the existing drug information for the drug and a review of the existing warnings and precautions.
It said the new drug information was updated as a precautionary measure and included the risk of severe liver damage and gastrointestinal bleeding.
It said it was reviewing information in the MHRA database which was available to all the public before the approval of the new drug application.
The MHRA said it had received reports of severe gastrointestinal bleeding in patients taking orlistat and there were cases of liver damage.
The agency said the risk of serious liver injury was also increased in patients with a history of liver disease.
The MHRA said it had received a number of reports of patients experiencing severe liver injuries and that there was a case of severe liver injury in patients taking orlistat, although this has been under study for several years.
The drug was included in the MHRA Prescription Medicines List, which has been updated on a case-by-case basis since January 2023. The list will be updated regularly as the list of the MHRA's updated Prescription Medicines List is updated.
The MHRA said it was reviewing its review of the previous list of medicines to include the risks of severe liver injury, and that the review had been taking the evidence for its recommendations.
The drug was also included in the drug list of the National Institutes of Health, which has been updated.
The drug is being prescribed for patients with liver failure, who have not been able to tolerate oral or intravenous anti-diabetic drugs, or those with a history of liver disease, and who are at a significantly increased risk of developing gastrointestinal bleeding.
The drug has been found to increase the risk of serious gastrointestinal and cardiovascular complications in patients with a history of gastrointestinal bleeding.
The MHRA said it was taking a step towards its review of the drug's safety in the new application.
It said the decision was based on information from the drug's manufacturers and its clinical trials. It also advised the MHRA to look at the existing warnings and precautions, as well as existing safety information on the drugs.
The drug has been approved for sale in the UK on prescription.
The MHRA, which is not regulated, said it was reviewing the current and future warnings and precautions in this application and that there is "no need to worry about safety concerns". It added that it was "reviewing" the current information on the drugs as part of the review.
The drug is also under study for several years and may have some risks.
MHRA spokesperson Paul Smith said: "This review is an important step towards addressing the current evidence and is part of the wider review of the existing drug information for the drug. The MHRA is now considering the review of the existing drugs and has also advised the MHRA to look at the existing warnings and precautions, and in particular to review all existing information on the drugs and the risk of serious gastrointestinal and cardiovascular complications."
This decision is part of a broader review of the drug's safety, which is currently ongoing.
The drug was previously used to treat a wide range of conditions, including high blood pressure, diabetes, high cholesterol, and heart attacks and strokes.
The drug is now used for other diseases, such as obesity, and there are concerns that its safety may be increased.
The MHRA said the drug was now considered an "approved" drug and should now only be prescribed in a patient with a history of liver disease. However, in recent years, new information has been added to the MHRA database, which is available to all the public and has been updated on a case-by-case basis since January 2023.
MHRA officials said they were still reviewing the current information on the drugs, but were not yet aware of any new warnings or precautions.
The MHRA said it was working with the FDA to investigate new information on the drugs, as well as the safety profile of the drugs and whether they were being used appropriately.
In May 2023, the drug was approved for sale in the UK on prescription.
Sold and Supplied by Healthylife Pharmacy
This product is a Prescription Only Medicine (S4) and is sold by Healthylife Pharmacy, an independently owned and operated pharmacy business. This prescription product requires a valid Australian script.
Healthylife provides general product information such as nutritional information, country of origin and product packaging for your convenience. This information is intended as a guide only, including because products change from time to time. Please read product labels before consuming. For therapeutic goods, always read the label and follow the directions for use on pack. If you require specific information to assist with your purchasing decision, we recommend that you contact the manufacturer via the contact details on the packaging or email us at [email protected]. Product ratings and reviews are taken from various sources including Bazaarvoice. Healthylife does not represent or warrant the accuracy of any statements, claims or opinions made in product ratings and reviews.
Healthylife Product InformationThis product is a Prescription Only Medicine (S4) in a quantity exceeding the range set forth in the safe use information included in the package. However, the 90-Day Supply indicates a 90-Day Supply before shipping. If you have any questions about why this product is sold, administer it and store it in a dry, cold and moisture-protected location. If you require specific information tointerstitialed your order before placing your order, please contact the manufacturer via the contact details on the packaging or email us at [email protected]. This product requires a valid Australian script. Please read the label and follow the directions for use.
Healthylife StorageHealthylifeapes Product Information
Qiao Guo and Jin Yong are Pharmacistliterally, Ltd. (US)Pricing andPrivacy Notice (The National Prescription Drug Program) (NPDP) is a statement signed by a pharmacist with an Australian, Australian or New Zealand donor or authorised representative.
Stade de France Pharmacy